查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011270

囊腫纖維化市場：按產品類型、給藥途徑、最終用戶和分銷管道分類 - 2026-2032年全球市場預測

Cystic Fibrosis Market by Product Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計囊腫纖維化市場在 2025 年的價值為 70.7 億美元，在 2026 年成長至 77.1 億美元，到 2032 年達到 136.1 億美元，年複合成長率為 9.79%。

主要市場統計數據
基準年 2025 70.7億美元
預計年份：2026年 77.1億美元
預測年份 2032 136.1億美元
複合年成長率 (%) 9.79%

針對囊腫纖維化領域產業和政策相關人員面臨的治療挑戰、臨床照護複雜性和策略重點，制定權威框架。

囊腫纖維化是一種遺傳性多重器官疾病，需要臨床、監管和商業部門持續協調努力。儘管分子診斷和治療方法創新技術的進步改變了人們對疾病修正治療的預期，但治療可近性、藥物依從性和長期管理方面仍然存在的挑戰，使得疾病始終處於專科診療的前沿。產業、臨床服務和政策利益相關人員必須權衡突破性治療方法的潛力與確保供應連續性、與支付方合作以及以患者為中心的醫療保健服務的切實可行的策略。

我們將評估正在重塑囊腫纖維化護理路徑和相關人員在真實臨床實踐中的優先事項的重大臨床、技術和商業性變化。

囊腫纖維化領域正在發生多項變革性變化，這些變化共同重塑了臨床預期和商業策略。在治療方面，標靶調變器的出現和不斷改進正將治療重點從症狀控制轉向緩解疾病，從而改變長期臨床路徑，並提升基於基因型決策的重要性。隨著這些藥物拓寬患者的預後範圍，臨床醫生和醫療保健系統需要調整監測通訊協定、合併症管理和護理過渡流程。

本研究評估了 2025 年實施的價格調整如何重組了整個囊腫纖維化治療生態系統的供應鏈策略、採購慣例和營運應對措施。

2025年實施的貿易政策調整和關稅措施對囊腫纖維化治療相關供應鏈的經濟效益和籌資策略產生了重大影響。部分藥品原料和成品的關稅上調改變了生產商和經銷商的收貨成本，促使他們即時採取應對措施，例如與供應商重新談判合約條款、重新評估採購區域，以及盡可能加快關鍵部件的在地採購。這些務實的措施旨在緩解不斷上漲的成本壓力，同時確保依賴持續治療的患者的藥物供應。

基於精細細分的洞察，將治療領域、給藥途徑、醫療保健環境和分銷管道與患者結果和商業策略聯繫起來。

透過分析各細分市場的趨勢，可以發現每個治療領域、給藥途徑、終端用戶環境和分銷管道所面臨的獨特機會和營運重點。按產品類型分析治療方法，抗發炎藥物和抗生素對於治療和控制與急性和慢性感染疾病以及潛在遺傳疾病相關的發炎併發症的症狀仍然至關重要。祛痰藥和胰酶製劑在日常症狀管理和營養支持中繼續發揮關鍵作用，兩者都需要穩定的供應和患者的依從性才能維持臨床療效。 CFTR調變器療法帶來了治療模式的最顯著轉變。在該類藥物中，聯合治療，例如elexacaftol/tezacaftol/ibacaftol、ibacaftol單藥療法、lumacaftol/ibacaftol和tezacaftol/ibacaftol，已展現出不同的基因型特異性療效，從而推動了基因型特異性治療路徑的發展，進而影響處方行為、伴隨診斷的使用和長期護理計劃。

從區域比較的觀點，重點關注美洲、歐洲、中東、非洲和亞太地區的進入因素、監管差異和證據優先事項。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管方法和准入框架有顯著影響。在美洲，高度整合的專科醫療網路和成熟的保險公司報銷管道正在推動基因型導向治療方法的早期應用。成熟的註冊登記系統和病患支援體系為這些療法提供了支持，有助於收集核准後的證據。這些系統通常強調療效驗證和結果追蹤，凸顯了與保險公司合作確保永續准入的重要性。

企業層面的策略分析，重點在於囊腫纖維化治療領域持續成功所必需的科學差異化、夥伴關係模式和業務永續營運。

產業參與者佔據著廣泛的戰略地位，這反映了他們在藥物發現、開發、生產和商業化方面的多元化能力。成熟的生物製藥創新者憑藉著深厚的臨床和監管專業知識，持續推動下一代調變器和聯合治療的研發。同時，小規模的生物技術公司和大學衍生企業則在新型機制、基因編輯和遞送平台等領域的早期研究方面處於領先地位。合約開發和生產組織（CDMO）在擴大複雜製劑的生產規模方面發揮著至關重要的作用，而專業的經銷商和藥房服務供應商專注於透過整合物流和患者支援服務來確保治療的連續性。

為領導者提供實用的策略指導，以將創新、證據產生和交付韌性與支付方合作和以患者為中心的交付模式相結合。

產業領導者應採取多管齊下的策略，將治療方法與藥物可及性、供應穩定性以及實證醫學結合。優先發展基於基因型的研發和伴隨診斷合作，將提升新治療方法的臨床意義，並為臨床醫生和支付者提供更清晰的價值提案。同時，從研發早期階段就納入真實世界證據（RWE）項目，將有助於消除支付方對長期療效的擔憂，並提供可用於指南制定和醫保談判的可操作數據。

結合檢驗的臨床資訊來源、監管分析和供應鏈評估的穩健調查方法，確保了研究結果的可靠性、可重複性以及可操作性建議。

本分析整合了同行評審文獻、監管出版刊物、臨床試驗註冊數據以及來自行業和衛生監管機構的檢驗的官方聲明，旨在全面展現囊腫纖維化的治療現狀。在資料收集過程中，我們優先考慮一級資訊來源、監管決策和已建立的患者註冊數據，以確保研究結果能夠反映檢驗的臨床和政策進展。在討論營運或商業性實踐時，本分析參考了貿易和物流報告、監管指導文件以及已記錄的採購框架，以支持基於可觀察到的行業趨勢提出的建議。

整合關鍵主題，強調需要製定一項綜合策略，將科學突破與營運、支付方和以患者為中心的實施聯繫起來。

囊腫纖維化的治療現況既是重要的轉捩點，也面臨一系列實際挑戰。儘管科學進步已催生出能夠改變許多患者疾病進程的治療方法，但要最大限度地發揮這些療法的潛力，需要在研發、分銷和政策制定等各個環節合作。確保永續的治療可近性，除了創新之外，還需要供應鏈的韌性、支付方參與的證據收集以及以患者為中心的醫療服務模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：囊腫纖維化市場：依產品類型分類

  • 抗發炎藥
  • 抗生素
  • CFTR調變器療法
    • 埃萊克卡夫托、特扎卡夫托、伊巴卡夫托
    • 伊巴卡夫托爾
    • 盧馬卡夫托爾·伊巴卡夫托爾
    • 特扎卡夫托爾·伊巴赫托爾
  • 黏液溶解劑
  • 胰酶

第9章：囊腫纖維化市場：依給藥途徑分類

  • 吸入
  • 靜脈注射
  • 口服

第10章：囊腫纖維化市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章：囊腫纖維化市場：依通路分類

  • 物理藥房
    • 醫院藥房
    • 零售藥房
  • 網路藥房

第12章：囊腫纖維化市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：囊腫纖維化市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：囊腫纖維化市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國囊腫纖維化市場

第16章：中國囊腫纖維化市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AIT
  • Alaxia
  • Alcresta Therapeutics, Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • Merck & Co. Inc.
  • Novartis AG
  • Sionna Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4316E4E89581

The Cystic Fibrosis Market was valued at USD 7.07 billion in 2025 and is projected to grow to USD 7.71 billion in 2026, with a CAGR of 9.79%, reaching USD 13.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.07 billion
Estimated Year [2026] USD 7.71 billion
Forecast Year [2032] USD 13.61 billion
CAGR (%) 9.79%

An authoritative framing of cystic fibrosis therapeutic imperatives, clinical care complexities, and the strategic priorities facing industry and policy stakeholders

Cystic fibrosis is a genetically driven, multisystem disease that continues to demand coordinated clinical, regulatory, and commercial attention. Advances in molecular diagnostics and therapeutic innovation have reshaped expectations for disease-modifying care, while persistent challenges in access, adherence, and long-term management keep the condition at the forefront of specialist practice. Stakeholders across industry, clinical services, and policy must balance the promise of transformative therapies with pragmatic strategies for supply continuity, payer engagement, and patient-centered delivery.

The landscape now prioritizes precision interventions that target underlying protein dysfunction, complemented by agents that manage infection, inflammation, and nutritional needs. Simultaneously, the delivery ecosystem evolves: specialty pharmacy pathways, home-based administration models, and digital adherence tools are increasingly integral to maintaining outcomes. Clinicians and program managers are adapting care protocols while payers scrutinize long-term value and comparative effectiveness data.

Taken together, these dynamics make strategic clarity essential. Investors need to understand how therapeutic classes intersect with real-world utilization. Commercial teams must align pricing, contracting, and distribution with evolving care settings. Regulatory and health policy professionals are focused on ensuring that innovation translates into meaningful access. This introduction sets the stage for a deeper examination of transformative shifts, tariff impacts, segmentation nuances, regional variations, and recommended actions for leaders navigating the cystic fibrosis therapeutic environment.

Evaluating the profound clinical, technological, and commercial shifts reshaping cystic fibrosis care pathways and stakeholder priorities in real-world settings

The cystic fibrosis landscape is undergoing several transformative shifts that together are redefining clinical expectations and commercial strategies. At the therapeutic level, the emergence and iterative improvement of targeted modulators has moved care delivery from symptom control toward disease modification, altering long-term clinical pathways and elevating the importance of genotype-driven decision-making. As these agents extend the horizon of patient outcomes, clinicians and health systems must recalibrate monitoring protocols, comorbidity management, and transition-of-care processes.

Concurrently, innovation is not limited to molecular therapies. Advances in inhalation technologies, home infusion practices, and patient support platforms are reshaping adherence and real-world effectiveness. Digital health interventions now play a more visible role in remote monitoring and telemedicine-delivered pulmonary care, and these modalities have accelerated expectations for convenience and continuity, particularly for populations with access challenges.

From a commercial vantage, payers and procurement groups are shifting toward outcomes-based conversations, requesting robust real-world evidence to support long-term cost and effectiveness claims. This demand for longitudinal data is prompting closer collaboration between manufacturers, clinical networks, and patient registries. Meanwhile, supply chain resilience has become a central consideration as stakeholders seek to mitigate disruptions and ensure uninterrupted patient access. Taken together, these shifts underscore a period of strategic recalibration: therapeutic innovation must be matched by sophisticated access planning, evidence generation, and patient-centric delivery models that collectively determine the long-term success of emerging and established therapies.

Assessing how tariff adjustments enacted in 2025 reshaped supply chain strategies, procurement practices, and operational responses across the cystic fibrosis treatment ecosystem

Trade policy adjustments and tariff actions implemented in 2025 have had a noticeable influence on supply chain economics and procurement strategies relevant to cystic fibrosis therapies. Increased duties on certain pharmaceutical inputs and finished goods altered landed costs for manufacturers and distributors, prompting immediate operational responses such as the renegotiation of supplier terms, reevaluation of sourcing geographies, and accelerated initiatives to localize critical components where feasible. These practical steps sought to contain cost pressures while preserving availability for patients who rely on continuous therapy.

In parallel, distributors and specialty pharmacies adjusted inventory management policies to reduce exposure to freight volatility and tariff uncertainty. Longer lead times and precautionary stocking in some supply nodes became more common as organizations aimed to prevent treatment interruptions. Health systems and hospital pharmacies also reassessed their procurement frameworks, emphasizing contractual flexibility and contingency clauses that account for tariff-driven cost variance.

Regulatory stakeholders and industry groups intensified engagement to clarify classification and duty treatment for specific therapeutic categories, particularly for complex biologics, combination products, and delivery devices. This dialogue emphasized the need for clear rulings that minimize administrative friction and support stable supply chains. Ultimately, the cumulative effect of tariff changes in 2025 has been to heighten attention on supply chain agility, encourage diversification of sourcing strategies, and motivate more robust collaboration among manufacturers, distributors, and health systems to protect patient access without compromising clinical care.

Nuanced segmentation-driven insights that connect therapeutic classes, administration pathways, care settings, and distribution channels to patient outcomes and commercial strategy

Segment-specific dynamics reveal differentiated opportunities and operational priorities across therapeutic classes, administration routes, end-user settings, and distribution channels. When therapies are analyzed by product type, anti-inflammatories and antibiotics remain essential for symptomatic control, addressing acute and chronic infectious and inflammatory complications that accompany the underlying genetic disorder. Mucolytics and pancreatic enzymes continue to play a critical role in day-to-day symptom management and nutritional support, each requiring consistent supply and patient adherence to sustain clinical benefit. CFTR modulator therapy has introduced the most notable inflection in treatment paradigms; within that class, combinations such as Elexacaftor Tezacaftor Ivacaftor, Ivacaftor alone, Lumacaftor Ivacaftor, and Tezacaftor Ivacaftor demonstrate varying efficacy across genotypes, and they have driven genotype-specific treatment pathways that influence prescribing behavior, companion diagnostic use, and long-term care planning.

Considering the route of administration, inhalation therapies provide targeted pulmonary delivery and are central to managing respiratory manifestations, while intravenous formulations are often reserved for severe or refractory infections requiring hospital-based care. Oral therapies, including many small-molecule modulators and supportive agents, facilitate outpatient management and enable broader adoption across home-based care settings. These administration distinctions influence adherence patterns, monitoring requirements, and reimbursement models.

End-user segmentation shows that home healthcare models increasingly accommodate complex regimens through home infusion services and telehealth-supported monitoring, thereby reducing inpatient resource use. Hospitals remain critical for acute care episodes, complex diagnostics, and initiation of certain intravenous regimens, while specialty clinics focus on coordinated multidisciplinary management and longitudinal follow-up. Distribution channel analysis underscores the dual importance of offline pharmacy networks-including hospital and retail pharmacy operations-for immediate dispensing and clinical integration, alongside online pharmacy channels that expand reach, enable subscription delivery models, and deliver ancillary digital support services. Together, these segmentation lenses clarify how therapeutic choice, mode of delivery, care setting, and distribution pathway converge to shape patient experience, clinical outcomes, and commercial strategy.

Comparative regional perspectives highlighting access drivers, regulatory heterogeneity, and evidence priorities across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert meaningful influence on clinical practice patterns, regulatory approaches, and access frameworks across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, highly integrated specialty care networks and established payer pathways foster early adoption of genotype-directed therapies, supported by mature registries and patient advocacy structures that facilitate post-approval evidence collection. These systems often emphasize value demonstration and outcomes tracking, and they underscore the importance of coordinated payer engagement to ensure durable access.

In Europe, the Middle East & Africa region, diverse regulatory frameworks and heterogeneous reimbursement environments create varying uptake timelines and access levels. Centralized approval pathways in some European markets coexist with national health technology assessment processes that scrutinize long-term effectiveness and budget impact. In the Middle East & Africa, infrastructure limitations and supply chain constraints can slow adoption, prompting tailored market-entry strategies and partnerships to build capacity and awareness. Across this combined region, stakeholders prioritize real-world evidence generation and local health economic analyses to support reimbursement decisions.

Asia-Pacific presents a mix of rapid innovation adoption in select markets alongside regulatory evolution and growing domestic biotech capability in others. National policies in key Asia-Pacific markets increasingly support precision medicine, and incremental expansions in diagnostic availability are enabling genotype-based prescribing. However, access can be uneven due to differences in reimbursement mechanisms and out-of-pocket cost structures. Across all regions, cross-border collaboration on regulatory harmonization, supply chain redundancy, and evidence generation is an active focus, as stakeholders attempt to reconcile the clinical promise of new therapies with pragmatic delivery and financing realities.

Strategic company-level analysis emphasizing scientific differentiation, partnership models, and operational resilience required for sustained success in cystic fibrosis therapeutics

Industry participants occupy a range of strategic positions that reflect diverse capabilities in discovery, development, manufacturing, and commercialization. Established biopharmaceutical innovators continue to leverage deep clinical and regulatory expertise to advance next-generation modulators and combination regimens, while smaller biotechnology firms and academic spinouts drive early-stage research into novel mechanisms, gene editing, and delivery platforms. Contract development and manufacturing organizations play a pivotal role in scaling production for complex formulations, and specialty distributors and pharmacy service providers focus on ensuring continuity of care through integrated logistics and patient support services.

Partnerships and strategic alliances remain central to advancing therapeutic portfolios and market access. Collaborative models that pair clinical development capabilities with commercialization infrastructure have enabled faster translation of promising compounds into clinical practice, while cross-sector agreements with diagnostics companies support genotype-directed prescribing. Licensing agreements and co-development arrangements help distribute risk and concentrate expertise where it most accelerates progress.

Investors and corporate decision-makers are attentive to the operational backbone required for sustained commercialization, including manufacturing scale-up, regulatory strategy alignment, and evidence generation to support long-term reimbursement. Companies that integrate real-world evidence programs early, demonstrate robust pharmacovigilance frameworks, and build scalable supply chain redundancies are better positioned to meet payer expectations and clinical needs. Ultimately, the most resilient organizations will be those that combine scientific differentiation with pragmatic operational discipline and proactive stakeholder engagement.

Actionable strategic guidance for leaders to align innovation, evidence generation, and supply resilience with payer engagement and patient-centered delivery models

Industry leaders should adopt a multi-dimensional strategy that aligns therapeutic innovation with access, supply resilience, and evidence generation. First, prioritizing genotype-driven development and companion diagnostic partnerships will increase the clinical relevance of new therapies, enabling clearer value propositions for clinicians and payers. Simultaneously, embedding real-world evidence programs from early phases of development will address payer concerns about long-term effectiveness and provide actionable data to inform guideline development and reimbursement negotiations.

Operationally, diversifying manufacturing and sourcing to reduce exposure to single geographic suppliers and tariff-sensitive input chains will protect continuity of supply. Leaders should evaluate nearshoring or dual-sourcing strategies and strengthen contractual terms with logistics providers to mitigate cost and availability volatility. In parallel, investing in specialty pharmacy relationships, home-care support models, and telehealth-enabled monitoring will improve adherence and patient experience, reducing the likelihood of acute exacerbations that drive higher system costs.

Commercial teams must engage payers proactively, advancing outcomes-based contracting mechanisms where appropriate and collaborating on registries that tie clinical metrics to reimbursement. Education initiatives for clinicians and patients should emphasize appropriate genotype testing and the clinical pathways that align with each therapeutic class. Finally, leaders should cultivate cross-sector collaborations-linking development, diagnostics, payers, and patient organizations-to ensure that innovation is accompanied by practical, patient-centered access solutions. Taken together, these actions create a strategic posture that balances innovation with real-world delivery considerations.

Robust methodological approach combining validated clinical sources, regulatory analysis, and supply chain assessment to ensure reliable, reproducible insights and actionable recommendations

This analysis synthesizes peer-reviewed literature, regulatory publications, clinical trial registries, and verified public statements from industry and health authorities to construct a comprehensive view of the cystic fibrosis therapeutic landscape. Data collection prioritized primary clinical sources, regulatory decisions, and established patient registry outputs to ensure that insights reflect validated clinical and policy developments. Where operational or commercial practices are discussed, the analysis references trade and logistics reporting, regulatory guidance documents, and documented procurement frameworks to ground recommendations in observable industry behavior.

Analytical methods combined qualitative synthesis with comparative policy analysis. Clinical efficacy and treatment paradigm descriptions derive from aggregated trial outcomes and guideline statements, while operational impact assessments applied scenario-based reasoning to evaluate supply chain and procurement responses. Evidence triangulation was used to confirm trends across independent sources, and sensitivity checks ensured that conclusions did not rely on single-source assumptions. Throughout, emphasis was placed on transparency of data provenance and the use of conservative language where uncertainty remains.

Limitations include the evolving nature of therapeutic approvals and regulatory guidance, which requires ongoing monitoring to capture new evidence and policy changes. To mitigate this, readers are encouraged to supplement the report with real-time regulatory updates and registries as part of iterative strategic planning. The methodology supports reproducibility and is designed to facilitate targeted follow-up analyses or bespoke data pulls for organizations with specific clinical or commercial questions.

Synthesis of pivotal themes emphasizing the necessity of integrated strategies that connect scientific breakthroughs with operational, payer, and patient-centered execution

The current moment in cystic fibrosis therapeutics presents both a watershed of opportunity and a set of practical challenges. Scientific progress has generated therapies capable of altering disease trajectories for many patients, but realizing their full potential requires coordinated action across development, distribution, and policy domains. Supply chain resilience, payer-engaged evidence generation, and patient-centric delivery models are equally important to innovation if durable access is to be achieved.

Strategic clarity will favor organizations that pair scientific differentiation with operational discipline. Those that invest early in real-world evidence, cultivate flexible supply strategies, and engage payers with transparent outcome measures will be positioned to translate clinical promise into widespread, sustainable benefit. Conversely, stakeholders that treat innovation and access as separate priorities risk leaving clinical gains unrealized due to avoidable barriers in procurement, reimbursement, or patient adherence.

In conclusion, the path forward is collaborative: integrating advances in therapeutics with pragmatic solutions for distribution, financing, and patient support will determine whether new therapies achieve their intended population-level impact. Continued monitoring, agile responses to policy changes, and a commitment to evidence-driven decision-making will be essential as the field continues to evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cystic Fibrosis Market, by Product Type

  • 8.1. Anti Inflammatories
  • 8.2. Antibiotics
  • 8.3. CFTR Modulator Therapy
    • 8.3.1. Elexacaftor Tezacaftor Ivacaftor
    • 8.3.2. Ivacaftor
    • 8.3.3. Lumacaftor Ivacaftor
    • 8.3.4. Tezacaftor Ivacaftor
  • 8.4. Mucolytics
  • 8.5. Pancreatic Enzymes

9. Cystic Fibrosis Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Cystic Fibrosis Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Cystic Fibrosis Market, by Distribution Channel

  • 11.1. Offline Pharmacy
    • 11.1.1. Hospital Pharmacy
    • 11.1.2. Retail Pharmacy
  • 11.2. Online Pharmacy

12. Cystic Fibrosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cystic Fibrosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cystic Fibrosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cystic Fibrosis Market

16. China Cystic Fibrosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AIT
  • 17.7. Alaxia
  • 17.8. Alcresta Therapeutics, Inc.
  • 17.9. AstraZeneca
  • 17.10. F. Hoffmann-La Roche Ltd
  • 17.11. Gilead
  • 17.12. Merck & Co. Inc.
  • 17.13. Novartis AG
  • 17.14. Sionna Therapeutics
  • 17.15. Teva Pharmaceutical Industries Ltd.
  • 17.16. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ELEXACAFTOR TEZACAFTOR IVACAFTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY IVACAFTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LUMACAFTOR IVACAFTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TEZACAFTOR IVACAFTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. G7 CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA CYSTIC FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA CYSTIC FIBROSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATOR THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CYSTIC FIBROSIS MARKET SIZE, BY OFFLINE PHARMACY, 2018-2032 (USD MILLION)